Pfizer’s biosimilar of Amgen, J&J’s anemia treatments gets FDA nod

(Reuters) – Pfizer Inc’s Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

Leave a Reply

Your email address will not be published. Required fields are marked *